ESR1 and breast carcinoma: We used affinity regression to infer the deregulated signaling pathways that drive expression changes in distinct breast cancer subtypes, to leverage the tumor model to predict drug sensitivity using breast cancer cell line mRNA and drug response data, and finally, to predict survival within the heterogeneous ER+, Luminal A subtype.